238 related articles for article (PubMed ID: 23933039)
1. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD.
Ding YS; Naganawa M; Gallezot JD; Nabulsi N; Lin SF; Ropchan J; Weinzimmer D; McCarthy TJ; Carson RE; Huang Y; Laruelle M
Neuroimage; 2014 Feb; 86():164-71. PubMed ID: 23933039
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates.
Gallezot JD; Weinzimmer D; Nabulsi N; Lin SF; Fowles K; Sandiego C; McCarthy TJ; Maguire RP; Carson RE; Ding YS
Neuroimage; 2011 May; 56(1):268-79. PubMed ID: 20869448
[TBL] [Abstract][Full Text] [Related]
3. Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress.
Logan J; Wang GJ; Telang F; Fowler JS; Alexoff D; Zabroski J; Jayne M; Hubbard B; King P; Carter P; Shea C; Xu Y; Muench L; Schlyer D; Learned-Coughlin S; Cosson V; Volkow ND; Ding YS
Nucl Med Biol; 2007 Aug; 34(6):667-79. PubMed ID: 17707807
[TBL] [Abstract][Full Text] [Related]
4. Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2.
Seneca N; Gulyás B; Varrone A; Schou M; Airaksinen A; Tauscher J; Vandenhende F; Kielbasa W; Farde L; Innis RB; Halldin C
Psychopharmacology (Berl); 2006 Sep; 188(1):119-27. PubMed ID: 16896954
[TBL] [Abstract][Full Text] [Related]
5. Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat.
Bourdet DL; Tsuruda PR; Obedencio GP; Smith JA
J Pharmacol Exp Ther; 2012 Apr; 341(1):137-45. PubMed ID: 22235148
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and in vivo evaluation of fluorine-18 and iodine-123 labeled 2beta-carbo(2-fluoroethoxy)-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane as a candidate serotonin transporter imaging agent.
Plisson C; Stehouwer JS; Voll RJ; Howell L; Votaw JR; Owens MJ; Goodman MM
J Med Chem; 2007 Sep; 50(19):4553-60. PubMed ID: 17705359
[TBL] [Abstract][Full Text] [Related]
7. Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[(18)F]FMeNER-D (2).
Takano A; Gulyás B; Varrone A; Maguire RP; Halldin C
Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1308-14. PubMed ID: 19300997
[TBL] [Abstract][Full Text] [Related]
8. SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study.
Takano A; Halldin C; Farde L
Psychopharmacology (Berl); 2013 Mar; 226(1):147-53. PubMed ID: 23090625
[TBL] [Abstract][Full Text] [Related]
9. Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2).
Nogami T; Takano H; Arakawa R; Ichimiya T; Fujiwara H; Kimura Y; Kodaka F; Sasaki T; Takahata K; Suzuki M; Nagashima T; Mori T; Shimada H; Fukuda H; Sekine M; Tateno A; Takahashi H; Ito H; Okubo Y; Suhara T
Int J Neuropsychopharmacol; 2013 Jun; 16(5):937-43. PubMed ID: 23067569
[TBL] [Abstract][Full Text] [Related]
10. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro.
Madras BK; Xie Z; Lin Z; Jassen A; Panas H; Lynch L; Johnson R; Livni E; Spencer TJ; Bonab AA; Miller GM; Fischman AJ
J Pharmacol Exp Ther; 2006 Nov; 319(2):561-9. PubMed ID: 16885432
[TBL] [Abstract][Full Text] [Related]
11. Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor.
Smith JA; Bourdet DL; Daniels OT; Ding YS; Gallezot JD; Henry S; Kim KH; Kshirsagar S; Martin WJ; Obedencio GP; Stangeland E; Tsuruda PR; Williams W; Carson RE; Patil ST
Int J Neuropsychopharmacol; 2014 Dec; 18(2):. PubMed ID: 25522383
[TBL] [Abstract][Full Text] [Related]
12. Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study.
Udvardi PT; Föhr KJ; Henes C; Liebau S; Dreyhaupt J; Boeckers TM; Ludolph AG
Drug Des Devel Ther; 2013; 7():1433-46. PubMed ID: 24348020
[TBL] [Abstract][Full Text] [Related]
13. Dopamine transporter genotype influences the physiological response to medication in ADHD.
Gilbert DL; Wang Z; Sallee FR; Ridel KR; Merhar S; Zhang J; Lipps TD; White C; Badreldin N; Wassermann EM
Brain; 2006 Aug; 129(Pt 8):2038-46. PubMed ID: 16760197
[TBL] [Abstract][Full Text] [Related]
14. Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults.
Matuskey D; Gallezot JD; Nabulsi N; Henry S; Torres K; Dias M; Angarita GA; Huang Y; Shoaf SE; Carson RE; Mehrotra S
J Psychopharmacol; 2023 Feb; 37(2):164-171. PubMed ID: 36515395
[TBL] [Abstract][Full Text] [Related]
15. Antidepressants modulate the in vitro inhibitory effects of propofol and ketamine on norepinephrine and serotonin transporter function.
Zhao Y; Sun L
J Clin Neurosci; 2008 Nov; 15(11):1264-9. PubMed ID: 18815045
[TBL] [Abstract][Full Text] [Related]
16. Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[¹⁸F]FMeNER-D₂.
Takano H; Arakawa R; Nogami T; Suzuki M; Nagashima T; Fujiwara H; Kimura Y; Kodaka F; Takahata K; Shimada H; Murakami Y; Tateno A; Yamada M; Ito H; Kawamura K; Zhang MR; Takahashi H; Kato M; Okubo Y; Suhara T
Int J Neuropsychopharmacol; 2014 Apr; 17(4):553-60. PubMed ID: 24345533
[TBL] [Abstract][Full Text] [Related]
17. An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxine.
Frankle WG; Robertson B; Maier G; Paris J; Asmonga D; May M; Himes ML; Mason NS; Mathis CA; Narendran R
Synapse; 2018 Mar; 72(3):. PubMed ID: 29216407
[TBL] [Abstract][Full Text] [Related]
18. Effects of tryptophan depletion on the binding of [11C]-DASB to the serotonin transporter in baboons: response to acute serotonin deficiency.
Milak MS; Ogden RT; Vinocur DN; Van Heertum RL; Cooper TB; Mann JJ; Parsey RV
Biol Psychiatry; 2005 Jan; 57(1):102-6. PubMed ID: 15607307
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine treatment of attention-deficit/hyperactivity disorder.
Eiland LS; Guest AL
Ann Pharmacother; 2004 Jan; 38(1):86-90. PubMed ID: 14742801
[TBL] [Abstract][Full Text] [Related]
20. Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology.
Wehmeier PM; Schacht A; Ulberstad F; Lehmann M; Schneider-Fresenius C; Lehmkuhl G; Dittmann RW; Banaschewski T
J Clin Psychopharmacol; 2012 Oct; 32(5):653-60. PubMed ID: 22926599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
